Virtu KCG Holdings LLC purchased a new stake in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 20,585 shares of the biopharmaceutical company’s stock, valued at approximately $147,000.
Several other hedge funds and other institutional investors have also bought and sold shares of TTPH. Dimensional Fund Advisors LP boosted its holdings in shares of Tetraphase Pharmaceuticals by 180.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock valued at $5,829,000 after buying an additional 408,078 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Tetraphase Pharmaceuticals by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after buying an additional 230,420 shares during the period. Morgan Stanley boosted its holdings in shares of Tetraphase Pharmaceuticals by 112.1% in the 1st quarter. Morgan Stanley now owns 317,717 shares of the biopharmaceutical company’s stock valued at $2,919,000 after buying an additional 167,919 shares during the period. Strs Ohio acquired a new position in shares of Tetraphase Pharmaceuticals in the 2nd quarter valued at about $577,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Tetraphase Pharmaceuticals by 17.0% in the 1st quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock valued at $2,880,000 after buying an additional 45,554 shares during the period. 40.92% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently commented on TTPH shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $13.00 price target (up from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. BidaskClub raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Piper Jaffray Companies started coverage on shares of Tetraphase Pharmaceuticals in a report on Monday, August 28th. They issued an “overweight” rating and a $14.00 price target for the company. Finally, ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. Tetraphase Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $12.96.
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) opened at 6.01 on Wednesday. The firm’s market capitalization is $306.83 million. Tetraphase Pharmaceuticals, Inc. has a 1-year low of $3.11 and a 1-year high of $9.93. The firm’s 50-day moving average is $6.76 and its 200-day moving average is $7.06.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. During the same period in the prior year, the company earned ($0.47) EPS. The firm’s revenue was up 28.2% compared to the same quarter last year. On average, equities analysts anticipate that Tetraphase Pharmaceuticals, Inc. will post ($2.91) EPS for the current year.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,155 shares of the stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $5.86, for a total transaction of $41,928.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 5.50% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Virtu KCG Holdings LLC Purchases Shares of 20,585 Tetraphase Pharmaceuticals, Inc. (TTPH)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/11/01/virtu-kcg-holdings-llc-purchases-shares-of-20585-tetraphase-pharmaceuticals-inc-ttph.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
What are top analysts saying about Tetraphase Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tetraphase Pharmaceuticals Inc. and related companies.